Update on brazikumab development programme
AstraZeneca announced the discontinuation of the brazikumab inflammatory bowel disease (IBD) development programme, an anti-IL-23 monoclonal antibody, being investigated for the treatment of Crohn’s disease (CD) and ulcerative colitis (UC)
The IBD development programme for brazikumab included the Phase IIb/III INTREPID trial in CD and the Phase II EXPEDITION trial in UC, and their respective open-label extension trials. The decision to discontinue brazikumab’s IBD development follows a recent review of brazikumab’s development timeline and the context of a competitive landscape that has continued to evolve. The timeline was impacted by delays that could not be mitigated following global events. No safety concerns were identified for patients in these trials.
90 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.